menu toggle

Q&A – How the tendency towards decentralized supply chains has changed in CGT

By AmerisourceBergen

Jennifer Fenwick, Senior Manager, Personalized Supply Chain at World Courier, part of Cencora, joins with Dr Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A about decentralized supply chains.
Decentralized clinical trials for CGTs
They delve into the reasons why therapy developers should consider investing in an integrated, digital supply chain for CGT, and why finding the right partners will be critical to their digital infrastructure success. 

Contact us

Connect with with our cell and gene therapy experts today. We look forward to hearing from you. 
Topics:
Cell and gene therapy Commercialization Distribution

Related Content

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Inverted color AmerisourceBergen icon
AmerisourceBergen
May 2023
Amerisourcebergen representatives at Asembia

Manufacturers

Three questions biopharma companies must ask when building a cell and gene commercialization strategy

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2023
Cell and gene therapy commercialization

Manufacturers

Webinar: Commercial supply chain strategies for cell and gene therapies

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2021
Commercial supply chain strategies for cell and gene therapies